NGR 6538 Exam
NGR 6538 EXAM 2 GUIDE QUESTIONS
AND ANSWERS
1.deficiency of serotonin linked to depression
2.increased levels of cortisol causing anxiety
3.reduced dopamine leading to parkinson's disease
4.excess of dopamine implicated in schizophrenia
Don't know?
Terms in this set (72)
Original
dopamine pathways
Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular
dopamine theory
excess of dopamine implicated in schizophrenia
mesolimbic pathway in schizophrenia
positive symptoms, too much dopamine
mesocortical pathway in schizophrenia
negative and cognitive symptoms, too little dopamine
Nigrostriatal pathway
Hyperactivity of dopamine in this pathway leads to movement disorders
Antipsychotics decrease dopamine
tuberofundibular pathway
Dopamine inhibits prolactin via this pathway. Antipsychotics decrease dopamine,
increasing prolactin, causing gynecomastia
NGR 6538 Exam
, NGR 6538 Exam
Antipsychotics with the lowest metabolic risk
Aripiprazole and Lurasidone
Antipsychotics with the highest metabolic risk
Quetiapine and olanzapine
Antipsychotic that increases QT prolongation
Geodon
Side effects of clozapine
Agranulocytosis (neutropenia) and seizures
Clozapine monitoring
CBC weekly for 6 months
then CBC every 2 weeks for 6 months
then CBC monthly
Clozapine adjunct
Prophylactic antiepileptics recommended
2nd generation antipsychotics recommended for bipolar depression
Lurasidone, olanzapine/fluoxetine, quetiapine
Olanzapine LAI adverse reaction
Delirium
Part of the brain that dopamine affects
midbrain
VMAT-2 inhibitors mechanism
Blocking dopamine transport reduces movement disorders
In aggressive patients, do not mix:
IM olanzapine with benzodiazepines (causes respiratory suppression)
Antipsychotic monitoring
NGR 6538 Exam
NGR 6538 EXAM 2 GUIDE QUESTIONS
AND ANSWERS
1.deficiency of serotonin linked to depression
2.increased levels of cortisol causing anxiety
3.reduced dopamine leading to parkinson's disease
4.excess of dopamine implicated in schizophrenia
Don't know?
Terms in this set (72)
Original
dopamine pathways
Nigrostriatal
Mesolimbic
Mesocortical
Tuberoinfundibular
dopamine theory
excess of dopamine implicated in schizophrenia
mesolimbic pathway in schizophrenia
positive symptoms, too much dopamine
mesocortical pathway in schizophrenia
negative and cognitive symptoms, too little dopamine
Nigrostriatal pathway
Hyperactivity of dopamine in this pathway leads to movement disorders
Antipsychotics decrease dopamine
tuberofundibular pathway
Dopamine inhibits prolactin via this pathway. Antipsychotics decrease dopamine,
increasing prolactin, causing gynecomastia
NGR 6538 Exam
, NGR 6538 Exam
Antipsychotics with the lowest metabolic risk
Aripiprazole and Lurasidone
Antipsychotics with the highest metabolic risk
Quetiapine and olanzapine
Antipsychotic that increases QT prolongation
Geodon
Side effects of clozapine
Agranulocytosis (neutropenia) and seizures
Clozapine monitoring
CBC weekly for 6 months
then CBC every 2 weeks for 6 months
then CBC monthly
Clozapine adjunct
Prophylactic antiepileptics recommended
2nd generation antipsychotics recommended for bipolar depression
Lurasidone, olanzapine/fluoxetine, quetiapine
Olanzapine LAI adverse reaction
Delirium
Part of the brain that dopamine affects
midbrain
VMAT-2 inhibitors mechanism
Blocking dopamine transport reduces movement disorders
In aggressive patients, do not mix:
IM olanzapine with benzodiazepines (causes respiratory suppression)
Antipsychotic monitoring
NGR 6538 Exam
